


IDS
Attach #4

SHEET 1 of 12

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 27373/36638A	Serial No. 09/964,042
 INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				Applicant Weichselbaum, R. et al.	
				Filing Date September 26, 2001	Group 1633

RECEIVED

U.S. PATENT DOCUMENTS

FEB 27 2002

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	4,769,331	09/06/88	Roizman et al.	435	69.1	
	A2	4,859,587	08/22/89	Roizman	435	68	
	A3	4,999,296	03/21/91	Kit et al.	435	69.1	
	A4	5,068,192	11/26/91	Cochran	435	235.1	
	A5	5,288,641	02/22/94	Roizman	435	320.1	
	A6	5,328,688	07/12/94	Roizman	424	205.1	
	A7	5,360,893	11/94	Owens et al.	530	350	
	A8	5,585,096	12/17/96	Martuza et al.	424	93.2	
	A9	5,593,879	01/97	Stellar et al.	435	240.1	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
	B1	EP 453242	10/23/91	EPO				
	B2	EP 243155	10/28/87	EPO				
	B3	WO 92/04050	03/19/92	PCT				
	B4	WO 96/00007	01/04/96	PCT				
	B5	WO 97/26904	07/31/97	PCT				

EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>10-6-02</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27373/36638A	Serial No. 09/964,042
FEB 15 2002 PATENT & TRADEMARK OFFICE		RECEIVED FEB 27 2002 Group 11638 CENTER 1600/2000	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

G	C1	Aas <i>et al.</i> , "Specific <i>P53</i> mutations are associated with <i>de novo</i> resistance to doxorubicin in breast cancer patients," <i>Nature Medicine</i> , 2(7): 811-814 (1996).
	C2	Ackermann <i>et al.</i> , "Identification by Antibody to a Synthetic Peptide of a Protein Specified by a Diploid Gene Located in the Terminal Repeats of the L Component of Herpes Simplex Virus Genome", <i>J. Virol.</i> , 58(3):843-850 (1986).
	C3	Ackermann <i>et al.</i> , "Characterization of Herpes Simplex Virus 1 α Proteins 0, 4, and 27 with Monoclonal Antibodies," <i>J. Virology</i> , 52(1):108-118 (1984).
	C4	Advani, S.J. <i>et al.</i> "Enhancement of Replication of Genetically Engineered Herpes Simplex Viruses by Ionizing Radiation: A New Paradigm for Destruction of Therapeutically Intractable Tumors," <i>Gene Therapy</i> , 5:160-165 (1998).
	C5	Andreansky <i>et al.</i> , "Evaluation of Genetically Engineered Herpes Simplex Viruses as Oncolytic Agents for Human Malignant Brain Tumors," <i>Cancer Research</i> , 57:1502-1509 (1997).
	C6	Andreansky <i>et al.</i> , "Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins," <i>Gene Therapy</i> , 5(1):121-130 (1998).
	C7	Barinaga, M., "Cell Suicide: By ICE, Not Fire", <i>Science</i> , 263:754-756 (1994).
	C8	Batistatou, A. <i>et al.</i> , "Aurintricarboxylic Acid Rescues PC12 Cells and Sympathetic Neurons from Cell Death Caused by Nerve Growth Factor Deprivation: Correlation with Suppression of Endonuclease Activity", <i>J. Cell Biol.</i> , 115(2):461-471 (1991).
	C9	Bischoff, J.R. <i>et al.</i> , "An Adenovirus Mutant That Replicates Selectively in p53-Deficient Human Tumor Cells," <i>Science</i> , 274: 373-376 (October, 1996).
	C10	Braun <i>et al.</i> , "Application of Denatured, Electrophoretically Separated, and Immobilized Lysates of Herpes Simplex Virus-Infected Cells for Detection of Monoclonal Antibodies and for Studies of the Properties of Viral Proteins," <i>J. Virol.</i> , 46:103-112 (1983).

EXAMINER	DATE CONSIDERED
<i>[Signature]</i>	18-6-02
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
27373/36638ASerial No.
09/964,042

INFORMATION DISCLOSURE STATEMENT

RECEIVED

(Use several sheets if necessary)

Applicant
Weichselbaum, R. et al.Filing Date
September 26, 2001Group
1633

FEB 27 2002

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

<i>Q</i>	C11	Brown <i>et al.</i> , "Genetic Studies with Herpes Simplex Virus Type 1. The Isolation of Temperature-sensitive Mutants, their Arrangement into Complementation Groups and Recombination Analysis Leading to a Linkage Map," <i>J. Gen. Virol.</i> , 18:329-346 (1973).
	C12	Brown, D. "Gene Therapy 'Oversold' By Researchers, Journalists", <i>The Washington Post</i> , A22, Friday, December 8, 1995
	C13	Centifanto-Fitzgerald <i>et al.</i> , "Ocular Disease Pattern Induced By Herpes Simplex Virus is Genetically Determined By A Specific Region of Viral DNA", <i>J. Exp. Med.</i> , 155:475-489 (1982).
	C14	Chambers <i>et al.</i> , "Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a <i>scid</i> mouse model of human malignant glioma", <i>Proc. Natl. Acad. Sci., USA</i> , 92:1411-1415 (1995).
	C15	Chou and Roizman, "Herpes Simplex Virus 1 (HSV-1) Gene γ_1 34.5 Blocks the Neuroblastoma Cells from Cell Death (Apoptosis) Induced by Viral Infection," <i>J. Cell. Biochem., Keystone Symposia</i> , Supplement 10C, February 21-March 7, 1992, Abstract N303, p. 136.
	C16	Chou <i>et al.</i> , "Association of a M_r 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 α and premature shutoff of protein synthesis after infection with γ_1 34.5 mutants of herpes simplex virus 1," <i>Proc. Natl. Acad. Sci. (USA)</i> 92:10516-10520 (1995).
	C17	Chou <i>et al.</i> , "Isomerization of Herpes Simplex Virus 1 Genome: Identification of the <i>cis</i> -Acting and Recombination Sites within the Domain of the α Sequence", <i>Cell</i> , 41:803-811 (1985).
	C18	Chou <i>et al.</i> , "The γ_1 34.5 gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells," <i>Proc. Natl. Acad. Sci. (USA)</i> 89:3266-3270 (1992).
<i>J</i>	C19	Chou <i>et al.</i> , "The Herpes Simplex Virus 1 Gene for ICP34.5, Which Maps in Inverted Repeats, Is Conserved in Several Limited-Passage Isolates but Not in Strain 17syn+", <i>J. Virol.</i> , 64(3):1014-1020 (1990).

EXAMINER

DATE CONSIDERED

10-6-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27373/36638A	Serial No. 09/964,042
INFORMATION DISCLOSURE STATEMENT RECEIVED <i>(Use several sheets if necessary)</i>		Applicant Weichselbaum, R. et al.	
		Filing Date September 26, 2001	Group 1633

FEB 27 2002

OTHER DOCUMENTS RECEIVED (Name, Author, Title, Date, Pertinent Pages, etc.)		
J	C20	Chou <i>et al.</i> , "The Terminal α Sequence of the Herpes Simplex Virus Genome Contains the Promoter of a Gene Located in the Repeat Sequences of the L Component", <i>J. Virol.</i> , 57(2):629-637 (1986).
	C21	Chou, J. <i>et al.</i> , "Mapping of Herpes Simplex Virus-1 Neurovirulence to γ 34.5, a Gene Nonessential for Growth in Culture," <i>Science</i> , 250:1262-1266 (November, 1990).
	C22	Clem <i>et al.</i> , "Prevention of Apoptosis by a Baculovirus Gene During Infection of Insect Cells," <i>Science</i> , 254:1388-1399 (1991).
	C23	Coghlan, A., "Gene dream fades away", <i>New Scientist</i> , pp. 14-15 (November, 1995).
	C24	Corey <i>et al.</i> , "Infections with Herpes Simplex Viruses," <i>New England J. Medicine</i> , 314:686-691 (1986).
	C25	Culver, K.W. <i>et al.</i> , "In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors," <i>Science</i> , 256:1550-1552 (June, 1992).
	C26	Datta <i>et al.</i> , "Overexpression of Bcl-x _L by Cytotoxic Drug Exposure Confers Resistance to Ionizing Radiation-induced Internucleosomal DNA Fragmentation," <i>Cell Growth & Differentiation</i> , 6:363-370 (April, 1995).
	C27	Davidson <i>et al.</i> , "Location and Orientation of Homologous Sequences in the Genomes of Five Herpes Viruses," <i>J. Gen. Virol.</i> , 64:1972-1942 (1983).
	C28	Deiss <i>et al.</i> , "Functional Domains within the α Sequence Involved in the Cleavage-Packaging of Herpes Simplex Virus DNA", <i>J. Virol.</i> , 59:605-618 (1986).
	C29	DeLuca <i>et al.</i> , "Isolation and Characterization of Deletion Mutants of Herpes Simplex Virus Type 1 in the Gene Encoding Immediate-Early Regulatory Protein ICP4," <i>J. Virology</i> , 56(2):558-570 (1985).
	C30	Dolan <i>et al.</i> , "Status of the ICP34.5 gene in herpes simplex virus type 1 strain 17," <i>Journal General Virology</i> , 73(4):971-973 (1992).

EXAMINER	DATE CONSIDERED
<i>[Signature]</i>	<i>10/6/02</i>
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27373/36638A	Serial No. 09/964,042
		Applicant Weichselbaum, R. et al.	
		Filing Date September 26, 2001	Group 1633

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

RECEIVED

FEB 15 2002
U.S. PATENT & TRADEMARK OFFICE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

TECH CENTER 1600/2900		
JJ	C31	Ejercito <i>et al.</i> , "Characterization of Herpes Simplex Virus Strains Differing in their Effects on Social Behaviour of Infected Cells", <i>J. Gen. Virol.</i> , 2:357-364 (1968).
	C32	Field <i>et al.</i> , "The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice", <i>J. Hyg., Camb.</i> , 81:267-277 (1978).
	C33	Gagliardini <i>et al.</i> , "Prevention of Vertebrate Neuronal Death by the <i>crmA</i> Gene", <i>Science</i> , 263:826-828 (1994).
	C34	Gregory <i>et al.</i> , "Activation of Epstein-Barr Virus Latent Genes Protects Human B Cells From Death by Apoptosis," <i>Nature</i> , 349:612-614 (1991).
	C35	Hallahan, <i>et al.</i> "Spatial and temporal control of gene therapy using ionizing radiation," <i>Nature Medicine</i> , 1(8):786-791 (1995).
	C36	Hammer <i>et al.</i> , "Temporal Cluster of Herpes Simplex Encephalitis: Investigation by Restriction Endonuclease Cleavage of Viral DNA", <i>J. Infectious Diseases</i> , 141(4):436-440 (1980).
	C37	Hayward <i>et al.</i> , "Anatomy of herpes simplex virus DNA: Evidence for four populations of molecules that differ in the relative orientations of their long and short components", <i>Proc. Natl. Acad. Sci., USA</i> , 72(11):4243-4247 (1975).
	C38	Heise <i>et al.</i> , "ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents," <i>Nature Medicine</i> , 3(6):639-645 (1997).
	C39	Henderson, S., "Induction of <i>blc-2</i> Expression by Epstein Barr Virus Latent Membrane Protein 1 Protects Infected B Cells from Programmed Cell Death," <i>Cell</i> , 65:1107-1115 (1991).
	C40	Hollstein, M. <i>et al.</i> , "p53 Mutations in Human Cancers," <i>Science</i> , 253: 49-53 (July, 1991).
JJ	C41	Honess <i>et al.</i> , "Proteins Specified by Herpes Simplex Virus XI. Identification and Relative Molar Rates of Synthesis of Structural and Nonstructural Herpes Virus Polypeptides in the Infected Cell", <i>J. Virol.</i> , 12:1347-1365 (1973).

EXAMINER	DATE CONSIDERED
<i>[Signature]</i>	<i>10-2-02</i>

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

U.S. Department of Commerce
Patent and Trademark Office

FEB 27 2002

TECH CENTER 1600/2900

Form PTO-1449 (Modified)	Atty. Docket No. 27373/36638A	Serial No. 09/964,042
Applicant Weichselbaum, R. et al.		
(Use several sheets if necessary)	Filing Date September 26, 2001	Group 1633

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

9	C42	Houldsworth et al., "Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation," <i>Oncogene</i> , 16:2345-2349 (1998).
	C43	Hubenthal-Voss et al., "Mapping of Functional and Antigenic Domains of the $\alpha 4$ Protein of Herpes Simplex Virus 1", <i>J. Virol.</i> , 62:454-462 (1988).
	C44	Itoh et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," <i>Cell</i> , 66:233-243 (1991).
	C45	Javier et al., "Genetic and Biological Analyses of a Herpes Simplex Virus Intertypic Recombinant Reduced Specifically for Neurovirulence", <i>J. Virol.</i> , 61(6):1978-1984 (1987).
	C46	Johnson et al., "Why Do Neurons Die When Deprived of Trophic Factor?" <i>Neurobiology of Aging</i> , 10:549-552 (1989).
	C47	Katz et al., "Quantitative Polymerase Chain Reaction Analysis of Herpes Simplex Virus DNA in Ganglia of Mice Infected with Replication-Incompetent Mutants," <i>J. Virology</i> , 64(9):4288-4295 (1990).
	C48	Kauffman et al., "Pathogenesis of Viral Infections," in <i>Fundamental Virology</i> , Fields et al. (Eds.), Chapter 10, Raven Press, New York, pp.153-167 (1986).
	C49	Kehm et al., "Restitution of the UL56 gene expression of HSV-1 HFEM led to restoration of virulent phenotype; deletion of the amino acids 217 to 234 of the UL56 protein abrogates the virulent phenotype," <i>Virus Research</i> , 40:17-40 (1996).
	C50	Kieff et al., "Size, Composition, and Structure of the Deoxyribonucleic Acid of Herpes Simplex Virus Subtypes 1 and 2", <i>J. Virol.</i> , 8:125-132 (1971).
	C51	Kyte et al., "A Simple Method for Displaying the Hydropathic Character of a Protein," <i>J. Mol. Biol.</i> , 157:105-132 (1982).
9	C52	Larder et al., "Restoration of Wild-type Pathogenicity to an Attenuated DNA Polymerase Mutant of Herpes Simplex Virus Type 1", <i>J. Gen. Virol.</i> , 67:2501-2506 (1986).

EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>10-26-02</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)	RECEIVED U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27373/36638A	Serial No. 09/964,042
FEB 15 2002 U.S. Patent and Trademark Office TELE FAX CENTER 1-600-9200		Applicant Weichselbaum, R. et al.	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Filing Date September 26, 2001	Group 1633

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

SJ	C53	Linnemann <i>et al.</i> , "Transmission of Herpes-Simplex Virus Type 1 in a Nursery for The Newborn Identification of Viral Isolates By D.N.A. "Fingerprinting", <i>Lancet</i> , 1:964-966 (1978).
SJ	C54	Loo <i>et al.</i> , "Serial Passage of Embryonic Human Astrocytes in Serum-Free, Hormone-Supplemented Medium," <i>J. Neuroscience Research</i> , 28:101-109 (1991).
SJ	C55	Lord <i>et al.</i> , "Sequence of MyD116 cDNA: A novel myeloid differentiation primary response gene induced by IL6," <i>Nucleic Acid Research</i> , 18(9):2823 (1990).
SJ	C56	Lowe, S.W. <i>et al.</i> , "p53 Status and the Efficiency of Cancer Therapy in Vivo," <i>Science</i> , 266:807-810 (November, 1994).
SJ	C57	Mackem <i>et al.</i> , "Structural Features of the Herpes Simplex Virus α Gene 4, 0, and 27 Promoter-Regulatory Sequences Which Confer α Regulation on Chimeric Thymidine Kinase Genes," <i>J. Virology</i> , 44(3):939-949 (1982).
SJ	C58	Maclean <i>et al.</i> , "Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17 ⁺ between immediate early gene 1 and the 'a' sequence", <i>Journal of General Virology</i> , 72(3):631-639 (1991).
SJ	C59	MacLean <i>et al.</i> , "The R _L neurovirulence locus in herpes simplex virus type 2 strain HG52 plays no role in latency", <i>J. Gen. Virol.</i> , 72:2305-2310 (1991).
SJ	C60	Martuza, R.L. <i>et al.</i> , "Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant," <i>Science</i> , 252:854-856 (May, 1991).
SJ	C61	McGeoch <i>et al.</i> , "Complete DNA sequence of the short repeat region in the genome of herpes simplex virus type 1", <i>Nucleic Acids Research</i> , 14:1727-1745 (1986).
SJ	C62	McGeoch <i>et al.</i> , "The Complete DNA Sequence of the Long Unique Region in the Genome of Herpes Simplex Virus Type 1", <i>J. Gen. Virol.</i> , 64:1531-1574 (1988).

EXAMINER	DATE CONSIDERED
<i>[Signature]</i>	18/6/02
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

RECEIVED

SHEET 8 of 12

Form PTO-1449 (Modified)	FEB 27 2002 U.S. Department of Commerce Patent and Trademark Office TECH CENTER 1600/2900	Atty. Docket No. 27373/36638A	Serial No. 09/964,042
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant Weichselbaum, R. et al.	
		Filing Date September 26, 2001	Group 1633

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)			
	C63	McGoech <i>et al.</i> , "Comparative sequence analysis of the long repeat regions and adjoining parts of the long unique regions in the genomes of herpes simplex viruses types 1 and 2", <i>J. Gen. Virol.</i> , 72:3057-3075 (1991).	
	C64	Meignier <i>et al.</i> , "Construction and In Vivo Evaluation of Two Genetically Engineered Prototypes of Live Attenuated Herpes Simplex Virus Vaccines", <i>Vaccines</i> , 87, Cold Spring Harbor Laboratory, pp. 368-373 (1987).	
	C65	Meignier <i>et al.</i> , "In Vivo Behavior of Genetically Engineered Herpes Simplex Viruses R7017 and R7020. II. Studies in Immunocompetent and Immunosuppressed Owl Monkeys (<i>Aotus trivirgatus</i>)", <i>J. Infectious Diseases</i> , 162:313-321 (1990).	
	C66	Meignier <i>et al.</i> , "In Vivo Behavior of Genetically Engineered Herpes Simplex Viruses R7017 and R7020: Construction and Evaluation in Rodents", <i>J. Infectious Diseases</i> , 158: 602-614 (1988).	
	C67	Meignier <i>et al.</i> , "Virulence of and Establishment of Latency by Genetically Engineered Deletion Mutants of Herpes Simplex Virus 1", <i>Virology</i> , 162:251-254 (1988).	
	C68	Mineta <i>et al.</i> , "Treatment of Malignant Gliomas Using Ganciclovir-hypersensitive, Ribonucleotide Reductase-deficient Herpes Simplex Viral Mutant," <i>Cancer Research</i> , 54: 3963-3966 (1994).	
	C69	Mocarski <i>et al.</i> , "Site-specific inversion sequence of the herpes simplex virus genome: Domain and structural features", <i>Proc. Natl. Acad. Sci., USA</i> , 78:7047-7051 (1981).	
	C70	Mocarski <i>et al.</i> , "Structure and Role of the Herpes Simplex Virus DNA Termini in Inversion, Circularization and Generation of Virion DNA", <i>Cell</i> , 31:89-97 (1982).	
	C71	Moriuchi <i>et al.</i> , "Enhanced Tumor Cell Killing in the Presence of Ganciclovir by Herpes Simplex Virus Type 1 Vector-directed Coexpression of Human Tumor Necrosis Factor- α and Herpes Simplex Virus Thymidine Kinase," <i>Cancer Research</i> , 58:5731-5737 (1998).	

EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>10/6/02</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


RECEIVED

SHEET 9 of 12

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

FEB 8 2002



TECH CENTER 1600/2900

Atty. Docket No.
27373/36638ASerial No.
09/964,042Applicant
Weichselbaum, R. et al.Filing Date
September 26, 2001Group
1633

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C72	Morris Academic Press Dictionary of Science technology Academic Press Harcourt Brace Jovanich Publishers, pp. 917 and 2276 (1992).
	C73	Morse et al., "Anatomy of Herpes Simplex Virus (HSV) DNA", <i>J. Virol.</i> , 26(2):389-410 (1978).
	C74	Mulligan, R.C., "The Basic Science of Gene Therapy", <i>Science</i> , 260:926-930 (May, 1993).
	C75	Nagata et al., "The Fas Death Factor," <i>Science</i> , 267:1449-1456 (1995).
	C76	Orkin et al., "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy" (December, 1995).
	C77	Peppel et al., "A Simple and Fast Method to Extract RNA from Tissue Culture Cells," <i>BioTechniques</i> , 9(6):711-712 (1990).
	C78	Perry et al., "Characterization of the IE110 Gene of Herpes Simplex Virus Type 1", <i>J. Gen. Virol.</i> , 67:2365-2380 (1986).
	C79	Perry et al., "The DNA Sequences of the Long Repeat Region and Adjoining Parts of the Long Unique Region in the Genome of Herpes Simplex Virus Type 1," <i>J. Gen. Virol.</i> , 69:2831-2846 (1988).
	C80	Poffenberger et al., "A Noninverting Genome of a Viable Herpes Simplex Virus 1: Presence of Head-to-Tail Linkages in Packaged Genomes and Requirements for Circularization After Infection", <i>J. Virol.</i> , 53(2):587-595 (1985).
	C81	Poffenberger et al., "Characterization of a viable, noninverting herpes simplex virus 1 genome derived by insertion and deletion of sequences at the junction of components L and S", <i>Proc. Natl. Acad. Sci., USA</i> , 80:2690-2694 (1983).
	C82	Post et al., "A Generalized Technique for Deletion of Specific Genes in Large Genomes: α -Gene 22 of Herpes simplex Virus 1 is Not Essential for Growth", <i>Cell</i> , 25:227-232 (1981).
	C83	Post et al., "Cloning of reiterated and nonreiterated herpes simplex virus 1 sequences as BamHI fragments", <i>Proc. Natl. Acad. Sci., USA</i> , 77(7):4201-4205 (1980).

EXAMINER

DATE CONSIDERED

16/6/02


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

SHEET 10 of 12

Form PTO-1449 (Modified)

FEB 15 2002

FEB 27 2002
Department of Commerce
Patent and Trademark Office

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
27373/36638ASerial No.
09/964,042Applicant
Weichselbaum, R. et al.Filing Date
September 26, 2001Group
1633

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C84	Ram <i>et al.</i> , "Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells," <i>Nature Medicine</i> , 3(12):1354-1361 (1997).
	C85	Rawson <i>et al.</i> , "Death of Serum-free Mouse Embryo Cells Caused by Epidermal Growth Factor Deprivation," <i>J. Cell Biology</i> , 113:671-679 (1991).
	C86	Renfranz <i>et al.</i> , "Region-Specific Differentiation of the Hippocampal Stem Cell Line HiB5 upon implantation into the Developing Mammalian Brain," <i>Cell</i> , 66:713-729 (1991).
	C87	Roizman, B., in <i>Virology, Second Edition</i> , Field <i>et al.</i> (Eds.) Chapter 64, Raven Press Ltd., New York (1990).
	C88	Roizman, B., in <i>Fundamental Virology, Second Edition</i> , Field <i>et al.</i> (Eds.) Chapters 5 and 33-34, Raven Press Ltd., New York (1991).
	C89	Roizman <i>et al.</i> , "The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors," <i>Proc Natl. Acad. Sci. (USA)</i> 93:11307-11312 (1996).
	C90	Roller <i>et al.</i> , "Herpes Simplex Virus 1 RNA-Binding Protein U _s 11 Negatively Regulates the Accumulation of a Truncated Viral mRNA," <i>J. Virology</i> , 65(11):5873-5879 (1991).
	C91	Ryder <i>et al.</i> , "Establishment and Characterization of Multipotent Neural Cell Lines Using Retrovirus Vector-Mediated Oncogene Transfer", <i>J. Neurobiol.</i> , 21:356-375 (1990).
	C92	Sanger <i>et al.</i> , "DNA sequencing with chain-terminating inhibitors", <i>Proc. Natl. Acad. Sci., USA</i> , 74:5463-5467 (1977).
	C93	Sentman <i>et al.</i> , "bcl-2 Inhibits Multiple Forms of Apoptosis but Not Negative Selection in Thymocytes," <i>Cell</i> , 67:879-888 (1991).
	C94	Sheldrick <i>et al.</i> , "Inverted-Repetitions in the Chromosome of Herpes Simplex Virus", <i>Cold Spring Harbor Symp. Quant. Biol.</i> , 39:667-678 (1975).
	C95	Shih <i>et al.</i> , "Expression of hepatitis B virus S gene by herpes simplex virus type 1 vectors carrying α - and β -regulated gene chimeras," <i>Proc. Natl. Acad. Sci. (USA)</i> 81:5867-5870 (1984).

EXAMINER

DATE CONSIDERED

16/10/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

FEB 27 2002

SHEET 11 of 12

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office
TECH CENTER 1600/2900Atty. Docket No.
7373/36638ASerial No.
09/964,042

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Weichselbaum, R. et al.Filing Date
September 26, 2001Group
1633

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C96	Snyder <i>et al.</i> , "Multipotent Neural Cell Lines Can Engraft and Participate in Development of Mouse Cerebellum," <i>Cell</i> , 68:33-51 (1992).
	C97	Steller, H., "Mechanisms and Genes of Cellular Suicide," <i>Science</i> , 267:1445-1449 (1995).
	C98	Stevens <i>et al.</i> , "Restriction of Herpes Simplex Virus By Macrophages", <i>J. Exp. Medicine</i> , 133:19-38 (1971).
	C99	Strasser <i>et al.</i> , "bcl-2 Transgene Inhibits T Cell Death and Perturbs Thymic Self-Censorship," <i>Cell</i> , 67:889-899 (1991).
	C100	Taha <i>et al.</i> , "A Variant of Herpes Simplex Virus Type 2 Strain HG52 with a 1.5 kb Deletion in R _L between 0 to 0.02 and 0.81 to 0.83 Map Units Is Non-neurovirulent for Mice", <i>J. Gen. Virol.</i> , 70:705-716 (1989).
	C101	Taha <i>et al.</i> , "The Herpes Simplex Virus Type 2 (HG52) Variant JH2604 Has a 1488 bp Deletion which Eliminates Neurovirulence in Mice", <i>Journal of General Virology</i> , 70(11):3073-3078 (1989).
	C102	Thompson <i>et al.</i> , "Biological Characterization of a Herpes Simplex Virus Intertypic Recombinant Which Is Completely and Specifically Non-Neurovirulent", <i>Virology</i> , 131:171-179 (1983).
	C103	Thompson <i>et al.</i> , "Physical Location of a Herpes Simplex Virus Type-1 Gene Function(s) Specifically Associated with a 10 Million-Fold Increase in HSV Neurovirulence", <i>Virology</i> , 131:180-192 (1983).
	C104	Thompson <i>et al.</i> , "Rescue of a Herpes Simplex Virus Type 1 Neurovirulence Function with a Cloned DNA Fragment", <i>J. Virology</i> , 35(2):504-508 (1985).
	C105	Thompson <i>et al.</i> , "Vaccine potential of a live avirulent herpes simplex virus," <i>Microbial Pathogenesis</i> , 1:409-416 (August, 1986).
	C106	Thompson <i>et al.</i> , "Functional and Molecular Analyses of the Avirulent Wild-Type Herpes Simplex Virus Type 1 Strain KOS, <i>J. Virology</i> , 58(1):203-211 (1986).

EXAMINER	DATE CONSIDERED
<i>[Signature]</i>	10/6/02
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

RECEIVED

SHEET 12 of 12

Form PTO-1449 (Modified)

O I P
P A T E N T & T R A D E M A R K O F F I C E
FEB 15 2002

FEB 27 2002

U.S. Department of Commerce

Patent and Trademark Office

TECH CENTER 1600/2900

Atty. Docket No.

27373/36638A

Serial No.

09/964,042

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Weichselbaum, R. et al.Filing Date
September 26, 2001Group
1633

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C107	Thompson <i>et al.</i> , "Herpes Simplex Virus Neurovirulence and Productive Infection of Neural Cells Is Associated with a Function Which Maps between 0.82 and 0.832 Map Units on the HSV Genome," <i>Virology</i> , 172(2):435-450 (1989).
	C108	Varmuza <i>et al.</i> , "Signals for Site-Specific Cleavage of HSV DNA: Maturation Involves Two Separate Cleavage Events at Sites Distal to the Recognition Sequences", <i>Cell</i> , 41:793-802 (1985).
	C109	Vlazny <i>et al.</i> , "Site-specific cleavage/packaging of herpes simplex virus DNA and the selective maturation of nucleocapsids containing full-length viral DNA", <i>Proc. Natl. Acad. Sci., USA</i> , 79:1423-1427 (1982).
	C110	Wadsworth <i>et al.</i> , "Anatomy of Herpes Simplex Virus DNA", <i>J. Virol.</i> , 15(6):1487-1497 (1975).
	C111	Warren <i>et al.</i> , "Isolation of Latent Herpes Simplex Virus from the Superior Cervical and Vagus Ganglia of Human Beings," <i>New England Journal Medicine</i> , 298:1068-1070 (1978).
	C112	Whitley, R.J. <i>et al.</i> , "Replication, Establishment of Latency, and Induced Reactivation of Herpes Simplex Virus γ_1 34.5 Deletion Mutants in Rodent Models," <i>J. Clin. Invest.</i> , 91:2387-2843 (June, 1993).
	C113	Whitley, "Herpes Simplex Viruses", pp. 1843-1887 in <i>Virology</i> , Second Ed., Chapter 66 Fields <i>et al.</i> , (eds.), Raven Press, New York (1990).
	C114	Williams, G.T., "Programmed Cell Death: Apoptosis and Oncogenesis," <i>Cell</i> , 65:1097-1098 (June, 1991).
	C115	Advani, et al., "Replication-competent, Nonneuroinvasive Genetically Engineered Herpes Virus Is Highly Effective in the Treatment of Therapy-resistant Experimental Human Tumors ¹ ," <i>Cancer Research</i> 59:2055-2058 (1999)
	C116	Carpenter, et al., "Sequences of the bovine herpesvirus 1 homologue of herpes simplex virus type-1 α -trans-inducing factor (UL48)," <i>GENE</i> 119:259-263 (1992)
	C117	Biosis Accession No. XP002141884

EXAMINER

DATE CONSIDERED

10/16/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.